7 out of 10 COVID-19 patients in hospital will have long-haul symptoms

Credit: CC0 Public Domain

In a new study from Stanford University, researchers found that many hospitalized COVID-19 patients will have long-haul symptoms.

A wide swath of lingering health issues plagued more than 70% of these patients.

There have been a lot of news commentaries and scientific articles talking about long-term COVID symptoms.

But few had dug into the scientific evidence deeply enough to show the full range, how long they lasted and whom they affected.

In the study, the team reviewed 45 studies that were published between January 2020 and March 2021. The studies included more than 9,700 COVID-19 patients. Of those, 83% had been hospitalized.

They found that 72.5% of study participants reported still having at least one of 84 persistent symptoms or clinical signs, with the most common being fatigue (40%), shortness of breath (36%), sleep disorders (29%), inability to concentrate (25%), depression and anxiety (20%), and general pain and discomfort (20%).

Other problems reported by patients included loss of taste and smell, memory loss, chest pain and fevers.

Persistent symptoms were defined as those lasting at least 60 days after diagnosis, symptom onset or hospital admission, or at least 30 days after recovery from acute illness or hospital discharge.

The team says if even a portion of these patients requires continuing care, they could pose an immense public health burden.

If something on the order of 70% of those coming out of moderate to serious COVID-19 is showing persisting symptoms, that is a huge number.

It’s astonishing how many symptoms are part of what’s now being referred to as long COVID.

If you care about COVID-19, please read studies about people with severe COVID-19 have too much of this stuff in blood and findings of this nutrient supplement may help prevent severe COVID-19, boost recovery.

For more information about COVID-19 prevention and treatment, please see recent studies about this very common drug for heart disease may reduce COVID-19 risk and results showing that this new drug 10 times more effective fighting COVID-19.

The study is published in JAMA Network Open. One author of the study is Dr. Steven Goodman.

Copyright © 2021 Knowridge Science Report. All rights reserved.